Mission Statement, Vision, & Core Values (2026) of Sichuan Hexie Shuangma Co., Ltd.

Sichuan Hexie Shuangma Co., Ltd. (SZ:000935) has rewritten its corporate playbook, evolving from cement producer to a diversified force centered on biotechnology and fund management, driving a remarkable rise in profitability from 0.85 billion RMB in 2016 to 9.85 billion RMB in 2023 as private equity investments-now the company's primary engine-accounted for 86% of 2023 net profit; with an enterprise value around $14.3 billion, Hexie Shuangma's mission to leverage private equity expertise to back high-growth biotech firms (notable stakes include Hangzhou Qunhe Information Technology Co., which has applied for an HKEX listing, and Fourier, a medical rehabilitation and academic-research robotics specialist) aligns with a vision of becoming a leading player in biotech and private equity, guided by core values of integrity, innovation, continuous improvement, transparency and collaborative value creation for shareholders, employees and communities.

Sichuan Hexie Shuangma Co., Ltd. (000935.SZ) - Intro

• Formerly a traditional cement manufacturer, Sichuan Hexie Shuangma Co., Ltd. (000935.SZ) has completed a strategic transformation toward private equity investment, fund management, and biotechnology.
• Enterprise value is approximately $14.3 billion, reflecting its material presence in China's investment landscape.

• Net profit grew from RMB 0.85 billion in 2016 to RMB 9.85 billion in 2023, underscoring the effectiveness of the pivot to investment-driven operations.
• In 2023, private equity investments accounted for 86% of the company's net profit, making the investment arm the company's core earnings engine.

• Hangzhou Qunhe Information Technology Co. - applied for listing on the Hong Kong Stock Exchange, representing a potential liquidity and valuation catalyst.
• Fourier - robotics company focused on medical rehabilitation and academic research solutions, aligning with the company's biotechnology emphasis.

• To redeploy legacy industrial capital into scalable, high-impact private equity and biotechnology platforms, generating sustainable returns while supporting innovation in healthcare and technology.

• To be a leading China-based investment and biotech group that transforms industrial heritage into future-facing enterprises, delivering value to shareholders and strategic partners through disciplined fund management and targeted biotech incubation.

• Capital discipline - prioritize investments with clear valuation discipline and exit pathways.
• Innovation orientation - back technologies and platforms that advance medical, research, and industrial applications.
• Governance and transparency - maintain robust fund-management practices and disclosure consistent with public‑market standards.
• Long-term value creation - focus on sustainable growth across portfolio companies, balancing near-term returns with strategic positioning.

• Scale private equity as the primary profit engine while selectively maintaining legacy asset knowledge where it adds strategic value.
• Deepen biotechnology and medical-technology exposure (e.g., robotics for rehabilitation) to capture growth in China's health-tech sector.
• Use public listings and exits (such as potential HKEX IPOs) to crystallize gains and re-cycle capital into new funds and ventures.

Sichuan Hexie Shuangma Co., Ltd. (000935.SZ) Overview

• Sichuan Hexie Shuangma's mission is to transition from a traditional cement manufacturing company to a diversified enterprise with a dual core business model focusing on biotechnology and fund management.
• The company aims to leverage its expertise in private equity investments to drive growth and profitability, shifting capital and management resources toward high-margin, high-growth opportunities.
• By investing in leading companies within the biotechnology sector, Sichuan Hexie Shuangma seeks to enhance its market position and deliver value to shareholders through both capital gains and recurring management fees.
• The mission reflects a commitment to innovation and adaptability in response to changing market dynamics, prioritizing talent, R&D partnerships, and selective strategic acquisitions.
• The strategic shift underscores the company's focus on high-growth sectors to achieve sustainable financial performance and reduce commodity exposure from legacy cement operations.
• This mission aligns with the broader trend of traditional manufacturing companies diversifying into high-tech and investment sectors to remain competitive.

• To become a leading hybrid enterprise that blends operational biotechnology assets with institutional-grade fund management capabilities, delivering compounded shareholder returns over a 3-5 year horizon.
• To build a biotechnology-focused investment ecosystem that supports clinical-stage innovation, commercialization, and cross-border partnerships.
• To grow recurring income from asset management to represent a progressively larger share of consolidated profits while maintaining disciplined capital allocation in industrial holdings.

• Innovation - prioritizing R&D-led investments and active portfolio value creation.
• Disciplined Investment - rigorous due diligence, stage-appropriate valuation discipline, and governance oversight for private equity and biotech stakes.
• Long-term Orientation - aligning incentives with long-term clinical and commercial milestones for investee companies.
• Transparency & Governance - enhancing disclosure, minority-protection clauses in private deals, and professional fund-management standards.
• Agility - reallocating capital from low-growth commodity segments to high-growth biotech and financial services opportunities.

• Reallocation of capital: phased reduction of low-return cement assets; proceeds directed to biotech equity and fund seed investments.
• Fund management buildout: establishing flagship private equity / venture funds targeting life sciences with institutional LPs to scale AUM and management-fee revenue.
• Direct biotech holdings: targeted investments in drug discovery, biologics manufacturing, and diagnostic platforms with exit horizons of 3-7 years.
• Operational synergies: leveraging internal capital markets experience to provide portfolio companies with governance, commercialization support, and cross-border licensing channels.

• Investment committee with external biotech and PE specialists to oversee deal selection, valuation, and exit planning.
• Portfolio concentration limits and step-down exposure rules to limit single-asset risk.
• Regular fair-value assessments for private holdings and enhanced disclosure practices to improve investor transparency.

Sichuan Hexie Shuangma Co., Ltd. (000935.SZ) - Mission Statement

• Advance medical rehabilitation: develop and commercialize therapies, devices, and rehab services that improve patient outcomes and reduce long-term care costs.
• Professional private equity stewardship: apply rigorous due diligence and active portfolio management to capture value in life sciences and healthcare tech.
• Sustainable growth and returns: balance long-term strategic investments with operational efficiency to produce stable shareholder value.
• Talent and research ecosystem: foster partnerships with academic, clinical, and tech institutions to accelerate translational research.
• Corporate responsibility: ensure compliance, quality control, and patient safety while contributing to regional healthcare capacity building.

• Leadership in biotech & rehab: target top-tier positions in rehabilitation technology niches and adjacent life-science segments.
• High-quality investment focus: prioritize investments with clear clinical pathways, scalable commercialization, and defensible IP.
• Operational excellence: improve margins through process optimization, digital health integration, and evidence-based care models.
• Stakeholder value creation: align governance and capital allocation to maximize returns for shareholders, patients, and partners.
• Scalable impact: replicate successful care models and platform companies across regional and national markets.

Sichuan Hexie Shuangma Co., Ltd. (000935.SZ) Vision Statement

• Integrity as the foundation: transparent governance, regulatory compliance, and responsible disclosure for public markets (listed as 000935.SZ on the Shenzhen Stock Exchange).
• Innovation-driven growth: continuous R&D investment to improve product efficiency and reduce environmental footprint.
• Operational excellence: scalable production, quality assurance, and cost discipline to protect margins and competitiveness.
• Partnerships and collaboration: strategic alliances across the value chain to expand market access and share technology.
• Stakeholder value creation: balancing returns to shareholders with fair employee remuneration and community investment.

• Integrity - enforcing ethical business practices, supplier due diligence, and transparent reporting.
• Innovation - investing in process improvements, pilot projects, and product upgrades to meet market demand and regulatory standards.
• Commitment to excellence - continuous improvement frameworks, quality metrics, and performance-linked management incentives.
• Collaboration - joint ventures, supplier partnerships, and distribution alliances that amplify reach and efficiency.
• Value creation - corporate actions prioritized to deliver sustainable returns to shareholders while enhancing employee welfare and community resilience.

• Performance KPIs tied to safety, yield, cost per ton, and environmental metrics to ensure alignment between values and outcomes.
• Transparency mechanisms: timely financial disclosures, audit processes, and stakeholder communications to uphold integrity.
• Strategic investments: targeted capital allocation toward modernization, energy efficiency, and value-added product lines.